Phase 3 N=222 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=138 Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
COPD
Primary: Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count — 96.4 Percentage
N/A N=41 Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System
Pain
Primary: Narcotic Use (mg) — 113.8; 99.6 mg — p=<0.05
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
Phase 1 N=60 Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers
Healthy
Primary: AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a — 36682; 87085; 279477; 176866 (pg/ml)*hour
N/A N=48 Thyroid Hormone Dose Adjustment in Pregnancy
Pregnancy · Hypothyroidism
Primary: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation — 24; 21 participants
N/A N=116 Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery
Spine Surgery
Primary: Mean Pain Scores — 4.4; 5.3 verbal response scores — p=<0.001
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 2 N=84 S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Lung Cancer
Primary: Overall Survival — 21 months
Phase 2 N=22 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams
Phase 2 N=76 Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Prostate Cancer
Primary: Number of Participants With Adverse Events — 19; 22; 19; 16 participants
N/A N=59 Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women
Pain
Primary: Change in Pain From Baseline to IUD Insertion — 61; 68 change in visual analog scale score
Phase 1 N=13 MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Multiple Myeloma
Primary: Assessment of Safety of recMAGE-A3 + AS15 — 13; 8; 4; 0 participants
Phase 2 N=174 Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14) — 0.3196; 0.3076; 0.2795; 0.2726 Liters — p=<0.0001
N/A N=483 One-year Outcome After Prehospital Intubation
One-year Outcome After Prehospital Intubation
Primary: Mortality — 35 percentage of one year mortality